Diamyd® is uniquely positioned as the only investigational drug in the FDA’s Fast Track program for all stages of type 1 diabetes.
10-20% of the more than 463 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
The antigen-specific immunotherapy Diamyd® and the regenerative and immunomodulatory therapy Remygen® are disease-modifying investigational medicines in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
The efficacy of intralymphatic administration of Diamyd® on preserving the insulin producing ability in Type 1 Diabetes is being confirmed in the precision medicine Phase III trial DIAGNODE-3. Diamyd® is also being evaluated in the prevention Phase II trial DiaPrecise.